HOME >> BIOLOGY >> NEWS
Other highlights in the September 7 JNCI

ding ER activity in PR-negative breast cancer. "These data could have a profound translational clinical impact on directing therapeutic interventions for patients who have ER-positive tumors but who display a steroid hormoneresistant or independent phenotype," they write.

Contact:

  • Article: Kimberlee Barbour, Baylor College of Medicine, 713-798-4712, kbarbour@bcm.edu
  • Editorial: Kim Irwin, University of California Los Angeles, 310-206-2805, kirwin@mednet.ucla.edu

    Hirschsprung Disease Gene May Also Be Involved in Some Melanomas

    A new study has found that mutations in a gene involved in Hirschsprung disease--a rare disease of the colon that usually occurs in children--may also predispose carriers to malignant melanoma.

    Because the endothelin signaling pathway plays an important role in the differentiation and migration of melanocytes, the cells from which melanomas arise, Nadem Soufir, M.D., Ph.D., of the Hopital Bichat-Claude Bernard in Paris, and colleagues investigated whether mutations in the gene endothelin receptor B (EDNRB), which is involved in Hirschsprung disease, could also predispose individuals to malignant melanoma. They sequenced the gene in 137 patients with malignant melanoma and 130 matched control subjects.

    EDNRB mutations were identified in four control subjects and in 15 patients, 14 of whom carried mutations reported in Hirschsprung disease and/or resulted in loss of gene function. The authors found a direct association between melanoma risk and the presence of EDNRB mutations. They conclude that their data strongly suggest that EDNRB is involved in the predisposition of two different multigenic disorders, Hirschsprung disease and melanoma.

    Contact: Nadem Soufir, Hopital Bichat-Claude Bernard, nadem.soufir@bch.ap-hop-paris.fr

    Treatment
    '"/>



  • Contact: Sarah L. Zielinski
    jncimedia@oxfordjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    6-Sep-2005


    Page: 1 2 3 4

    Related biology news :

    1. Other highlights in the Aug. 7 JNCI
    2. Other highlights in the July 24 JNCI
    3. Other highlights from the July 10 JNCI
    4. Other highlights in JNCI, June 26
    5. Other highlights in JNCI, June 12
    6. Other highlights from the June 6 JNCI
    7. Other highlights in the May 16 JNCI
    8. Other highlights from the April 18 Journal of the National Cancer Institute
    9. Other highlights from the March 21 JNCI
    10. Other highlights in the March 7 JNCI
    11. Other highlights in the Feb. 21 JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: Other highlights the September JNCI

    (Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
    (Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
    (Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
    Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
    (Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
    (Date:12/17/2014)... New York, NY (PRWEB) December 16, 2014 ... undergone significant changes since 2013, which is why IBISWorld ... one, this industry continues to benefit from an intensified ... 2014, the proposal for new emission standards for power ... affected industry operators. According to IBISWorld Industry Analyst Sarah ...
    (Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
    (Date:12/17/2014)... December 17, 2014 Gene synthesis ... it has entered into a technology access and ... to apply DNA2.0’s proprietary protein engineering technology, known ... , “We are extremely excited that the global ... This proprietary bioengineering technology has now been ...
    Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
    Cached News: